Pfizer breast cancer drug hits midstage study goal

Pfizer's promising experimental breast cancer drug, palbociclib, meets study's survival goal

  • Excited fans get up close with One Direction wax figures

    Excited fans get up close with One Direction wax figures

    Excited fans get up close with One Direction wax figures

    Fans of the British boyband stood in line to get a chance to be in a photo shoot with the statues of the lads of One Direction -- Zayn Malik included -- at an exclusive preview at Madame Tussauds Singapore on 9 July 2015. …

  • How to pour the perfect cup of beer

    How to pour the perfect cup of beer

    How to pour the perfect cup of beer

    Pouring a perfect cup of beer that doesn’t overflow with foam is not easy if you’re not an expert. Master Brewer of Archipelago, Robert Beck, shows us how its done, with two different results — less foam, or more foam. …

  • Aide and SEA Games football squad pay tribute to Sabah quake victims

    Aide and SEA Games football squad pay tribute to Sabah quake victims

    Aide and SEA Games football squad pay tribute to Sabah quake victims

    Aide and SEA Games football squad pay tribute to Sabah quake victims at Tankong Katong Primary School. The Sabah quake tragedy hits home for Aide because he knew some of the victims personally. Footballer Sahil Suhaimi was also a former TKPS student. …

Drugmaker Pfizer Inc. said Monday that a midstage study of its experimental drug for advanced breast cancer, palbociclib, met the main goal.

The world's second-biggest drugmaker said the drug, combined with another medicine called letrozole, increased the time patients survived without tumors growing, compared with women just getting letrozole.

Shares of New York-based Pfizer jumped more than 4 percent early on and closed trading up 21 cents at $30.61 while the broader markets fell sharply.

Analysts are closely watching palbociclib, which is for postmenopausal women with certain tumor characteristics found in about 60 percent of patients with advanced breast cancer. It's seen as a potential huge seller.

Credit Suisse analyst Vamil Divan wrote to investors Monday that he expects the drug to produce annual global sales of $2.9 billion in 2023.

"We believe our forecasts are likely conservative at this point," particularly if palbociclib turns out to also work on lung and blood cancers, Divan wrote in a research note.

He reiterated his "Outperform" rating for Pfizer, saying he likes the company's stock "as a multi-year restructuring story" due to possible bonuses from its pipeline of experimental drugs, "shareholder-friendly capital allocation" and a low share price.

Shares had languished in the teens for several years, then nearly doubled from $17.45 over the past 29 months — still well below the share price for Pfizer's major competitors.

Divan noted Pfizer's comments Monday could raise expectations the company could apply for and receive palbociclib approval a little earlier than expected.

Pfizer said it plans to release detailed results from the latest study, called PALOMA-1, at the American Association for Cancer Research meeting in San Diego in early April.

The company is now enrolling patients in a late-stage test of palbociclib. Last April, the Food and Drug Administration designated it a breakthrough therapy, a recognition that helps speed up the review needed for approval.

___

Follow Linda A. Johnson at https://twitter.com/LindaJ_onPharma

Loading...

Latest News

Makanation